Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations.
about
Beta class II tubulin predominates in normal and tumor breast tissues.No significant role for beta tubulin mutations and mismatch repair defects in ovarian cancer resistance to paclitaxel/cisplatinReduced expression of p27 is a novel mechanism of docetaxel resistance in breast cancer cellsPaclitaxel Through the Ages of Anticancer Therapy: Exploring Its Role in Chemoresistance and Radiation TherapyAntimitotic drugs in the treatment of cancerNanoparticle-mediated drug delivery for treating melanomaMicrotubule-binding agents: a dynamic field of cancer therapeutics.Modulation of endogenous beta-tubulin isotype expression as a result of human beta(III)cDNA transfection into prostate carcinoma cellsUnderstanding the basis of drug resistance of the mutants of αβ-tubulin dimer via molecular dynamics simulationsParallel evolution under chemotherapy pressure in 29 breast cancer cell lines results in dissimilar mechanisms of resistanceResistance to Taxol in lung cancer cells associated with increased microtubule dynamics.Mechanisms of Taxol resistance related to microtubules.Role of multimodality treatment for lung cancer.Thymidine Phosphorylase/β-tubulin III expressions predict the response in Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel.Mechanisms of action and resistance to tubulin-binding agents.Intratumoral injection of taxol in vivo suppresses A549 tumor showing cytoplasmic vacuolization.Drug resistance to paclitaxel is not only associated with ABCB1 mRNA expression but also with drug accumulation in intracellular compartments in human lung cancer cell lines.Novel combination chemotherapy in the treatment of non-small cell lung cancer.Taxane pathway.Biological activity of 4-substituted methoxybenzoyl-aryl-thiazole: an active microtubule inhibitorNovel microtubule-targeting agents - the epothilones.An antimitotic and antivascular agent BPR0L075 overcomes multidrug resistance and induces mitotic catastrophe in paclitaxel-resistant ovarian cancer cellsTxr1: a transcriptional regulator of thrombospondin-1 that modulates cellular sensitivity to taxanes.Taxanes for advanced non-small cell lung cancer.A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells.Endometrial carcinoma: a review of chemotherapy, drug resistance, and the search for new agentsAlterations in tumor necrosis factor signaling pathways are associated with cytotoxicity and resistance to taxanes: a study in isogenic resistant tumor cells.Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial.Tailor-made chemotherapy for non-small cell lung cancer patients.Mucin 1-mediated chemo-resistance in lung cancer cells.Design, synthesis, and SAR studies of 4-substituted methoxylbenzoyl-aryl-thiazoles analogues as potent and orally bioavailable anticancer agentsPharmacogenetics and oncology treatment for breast cancer.Anticancer drugs from nature--natural products as a unique source of new microtubule-stabilizing agents.Crystallization and preliminary X-ray diffraction analysis of the beta subunit Yke2 of the Gim complex from Saccharomyces cerevisiae.Pharmacology, pharmacokinetics and pharmacogenomics of paclitaxel.Secondary mutations correct fitness defects in Toxoplasma gondii with dinitroaniline resistance mutationsParameters for individualizing systemic therapy in non-small cell lung cancerTargeting microtubules by natural agents for cancer therapy.Cathepsin L upregulation-induced EMT phenotype is associated with the acquisition of cisplatin or paclitaxel resistance in A549 cells.Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy.
P2860
Q21195178-3CE5E2FA-E0F3-4CFE-94A6-9C79A2BAB833Q24531843-91A4A58F-7A4C-4D75-B754-90C4B153E905Q24806463-3F94AE7F-3D93-4C81-AA89-493AE20ADAEBQ26775004-C7F76894-BC6A-439F-8896-3A5383C19A54Q26777317-8A778E05-6572-4170-A0D9-4F81DCC15E00Q26798379-628BABE1-7355-4A7E-A3EE-CFC9F58236BDQ27690249-EF32BB93-472D-45B9-833E-42A364C21D8AQ28348244-18559091-C11E-4A3E-AF3A-9CC90495BDE0Q28482107-D6DB3FDB-F23B-48F5-8F21-CF67730CF3A8Q28732256-BDF025F6-5E04-42D3-B76E-5C95CDA2F83DQ30856929-8D0A5C4A-26B0-4E52-BCE1-32BC1A5B3EEAQ33688044-E9818C6B-8627-4A73-A60D-5A9A3A6A4593Q33829263-0667D83F-0C3F-41E9-BAA6-1EBCF2D82CF5Q33903541-7F8A45CB-F6A4-4217-9986-BF59DFA3D674Q34074808-F9079595-13CD-4640-91A9-3D4A4FFF2E58Q34089072-9A839228-05CD-4807-8BD1-1F68658DC3BAQ34104738-80FDB05B-FEE2-422C-AD64-835A87DCE500Q34181910-B8BAC1CB-9474-4BC0-ACD0-1A3F440E6542Q34390370-A583D279-4909-44E2-91B6-43D338FB9363Q34576078-13AE71D9-06C8-475C-97B5-F2FF5810D491Q34611212-B34C1D71-934B-4B31-AD17-357DA4AD3E52Q34770077-D814C6EE-DFA3-4F59-ACC0-5624C6B4C21EQ34958852-54B9A66F-9181-418C-8CEB-DF6567CBEB9DQ35020524-22B88D75-EEC8-4C1D-8EBA-F099854ACCD1Q35084273-369D3413-EB21-45A8-8725-DF7BD5DBADF6Q35583750-AD16B551-E754-407F-98AF-F2D5F0A7D4BCQ36393078-6C002515-B652-41F4-ACB5-A7AF2F27E1DBQ36411072-23029515-D51D-45E5-8C0F-20C5CE6AB48FQ36430761-89D2C595-2047-4C2A-9166-CEE8633F44E3Q36507586-3FDA399B-CE12-46F8-9EA3-FCE951297543Q36584907-B146411C-4118-4620-9C57-39DD4466FB61Q36719659-7F909264-F8EF-4065-B51F-73C61D7E02D0Q36772390-C62B6286-597D-41D2-B903-8AA62DAC5ECEQ36812439-5F9E9E4C-1D56-4A85-8825-CB88E1CBAE4FQ36885663-E0093D7D-2DB7-48EF-A455-EC80C84E364FQ36936842-6F97A2D6-AA92-4B3D-BB6E-E2549EB80B01Q37398845-DB3E3AD7-4F98-430E-A21B-B6C6CD0AC376Q37623838-3042DEE8-FD23-42B7-AB5F-F388E5C94831Q37642507-C966784E-2C47-41C3-833A-FB263FD35951Q37684533-F9F70735-559A-4CA7-B506-6517A09A53F3
P2860
Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh
1999年學術文章
@zh-hant
name
Paclitaxel resistance in non-s ...... h beta-tubulin gene mutations.
@en
type
label
Paclitaxel resistance in non-s ...... h beta-tubulin gene mutations.
@en
prefLabel
Paclitaxel resistance in non-s ...... h beta-tubulin gene mutations.
@en
P2093
P1476
Paclitaxel resistance in non-s ...... h beta-tubulin gene mutations.
@en
P2093
J C Lorenzo
J J Sánchez
J L González-Larriba
P304
P356
10.1200/JCO.1999.17.6.1786
P407
P577
1999-06-01T00:00:00Z